

The Centers for Medicare & Medicaid Services' Office of Research, Development, and Information (ORDI) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact ORDI through e-mail at ORDI_508_Compliance@cms.hhs.gov.

**STATISTICAL COMPENDIUM:
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2006
ALASKA**

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC
TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY
TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES
SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65
SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER
SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74
SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84
SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES
APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES
APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES
APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
All	117,172	776	8,512	28,122	79,598	164	1,041,773	7,973	89,866	210,169	732,662	1,103
Age												
5 and younger	31,222	0	482	0	30,740	0	273,217	0	4,670	0	268,547	0
6-14	35,515	0	903	2	34,610	0	344,524	0	10,091	7	334,426	0
15-20	20,082	0	781	5,322	13,974	5	175,658	0	8,315	38,879	128,447	17
21-44	22,621	1	2,458	19,799	274	89	173,304	3	26,221	145,323	1,242	515
45-64	6,836	16	3,759	2,992	0	69	65,852	148	39,207	25,934	0	563
65-74	507	376	123	7	0	1	5,248	3,924	1,290	26	0	8
75-84	305	299	6	0	0	0	3,277	3,205	72	0	0	0
85 and older	84	84	0	0	0	0	693	693	0	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	64,684	517	4,260	20,944	38,799	164	564,846	5,331	45,720	154,781	357,911	1,103
Male	52,486	259	4,252	7,178	40,797	0	476,923	2,642	44,146	55,388	374,747	0
Unknown	2	0	0	0	2	0	4	0	0	0	4	0
Race												
White	46,632	152	4,481	11,948	29,925	126	405,827	1,383	46,628	85,976	270,979	861
African American	6,448	16	518	1,379	4,531	4	58,325	120	5,464	10,489	42,223	29
Other/unknown	64,092	608	3,513	14,795	45,142	34	577,621	6,470	37,774	113,704	419,460	213
Use of Nursing Facilities^c												
Entire year	75	13	61	1	0	0	673	136	536	1	0	0
Part year	109	16	89	4	0	0	1,104	158	901	45	0	0
None	116,988	747	8,362	28,117	79,598	164	1,039,996	7,679	88,429	210,123	732,662	1,103
Maintenance Assistance Status												
Cash	41,082	736	7,645	15,816	16,885	0	380,322	7,739	80,876	130,875	160,832	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	63,446	0	0	10,217	53,065	164	543,071	0	0	62,200	479,768	1,103
Other/unknown	12,644	40	867	2,089	9,648	0	118,380	234	8,990	17,094	92,062	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	117,172	776	8,512	28,122	79,598	164	1,041,773	7,973	89,866	210,169	732,662	1,103
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Benef(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3
ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}
NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ ^c	Rx \$ as a Percentage of All Medicaid		Number of Beneficiaries
						FFS \$ ^d		
All	54.0	7.4	\$585	\$79	\$5,930	9.9		117,172
Age								
5 and younger	52.6	2.4	200	85	4,162	4.8		31,222
6-14	43.2	2.9	263	90	3,390	7.7		35,515
15-20	52.4	4.7	481	102	7,497	6.4		20,082
21-44	66.6	11.8	875	74	7,352	11.9		22,621
45-64	76.8	43.4	3,166	73	16,015	19.8		6,836
65-74	75.5	37.8	2,303	61	19,554	11.8		507
75-84	66.9	39.2	2,029	52	21,477	9.4		305
85 and older	48.8	18.5	1,085	59	19,534	5.6		84
Unknown	0.0	0.0	0	0	0	0.0		0
Basis of Eligibility^e								
Aged	68.2	34.5	1,997	58	18,756	10.6		776
Disabled	80.9	48.1	4,238	88	27,155	15.6		8,512
Adults	63.2	7.5	471	63	4,939	9.5		28,122
Children	47.7	2.7	219	80	3,873	5.7		79,598
Unknown	62.2	13.1	1,367	104	11,632	11.8		164
Gender								
Female	57.6	8.5	602	71	5,970	10.1		64,684
Male	49.5	6.0	564	94	5,881	9.6		52,486
Unknown	0.0	0.0	0	0	0	0.0		2
Race								
White	57.1	9.5	781	82	6,099	12.8		46,632
African American	54.1	8.3	612	73	4,983	12.3		6,448
Other/unknown	51.7	5.7	440	77	5,902	7.4		64,092
Use of Nursing Facilities^f								
Entire year	92.0	75.7	7,010	93	119,936	5.8		75
Part year	93.6	90.2	6,927	77	104,678	6.6		109
None	53.9	7.3	575	79	5,765	10.0		116,988
Maintenance Assistance Status								
Cash	61.2	15.1	1,183	79	8,343	14.2		41,082
Medically needy	0.0	0.0	0	0	0	0.0		0
Poverty related	48.8	2.6	191	73	3,861	4.9		63,446
Other/unknown	56.5	6.4	620	97	8,472	7.3		12,644

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In ten states (DE, IA, IL, NC, NE, NY, TN, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In ten states (DE, IA, IL, NC, NE, NY, TN, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	Number of Rx, Percentage with:										Number	
	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ ^c	None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	0.8	\$66	9.9	46.0	43.1	4.2	4.1	1.6	0.9	\$667	117,172	1,041,773
Age												
5 and younger	0.3	23	4.8	47.4	50.0	1.8	0.7	0.0	0.0	476	31,222	273,217
6-14	0.3	27	7.7	56.8	38.8	2.4	1.6	0.3	0.1	350	35,515	344,524
15-20	0.5	55	6.4	47.6	44.3	4.3	2.7	0.8	0.3	857	20,082	175,658
21-44	1.5	114	11.9	33.4	45.1	8.4	8.6	3.0	1.4	960	22,621	173,304
45-64	4.5	329	19.8	23.2	27.0	9.2	19.4	12.8	8.3	1,663	6,836	65,852
65-74	3.7	223	11.8	24.5	25.0	9.7	22.3	12.8	5.7	1,889	507	5,248
75-84	3.7	189	9.4	33.1	18.7	10.5	20.3	8.9	8.5	1,999	305	3,277
85 and older	2.2	132	5.6	51.2	14.3	7.1	13.1	10.7	3.6	2,368	84	693
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility^e												
Aged	3.4	194	10.6	31.8	21.8	9.5	20.1	10.4	6.3	1,826	776	7,973
Disabled	4.6	401	15.6	19.1	28.7	10.2	19.9	12.3	9.7	2,572	8,512	89,866
Adults	1.0	63	9.5	36.8	46.1	7.6	7.0	2.1	0.4	661	28,122	210,169
Children	0.3	24	5.7	52.3	43.9	2.3	1.2	0.2	0.1	421	79,598	732,662
Unknown	1.9	203	11.8	37.8	31.7	11.6	14.0	4.3	0.6	1,730	164	1,103
Gender												
Female	1.0	69	10.1	42.4	45.0	4.8	4.7	2.0	1.1	684	64,684	564,846
Male	0.7	62	9.6	50.5	40.8	3.5	3.3	1.2	0.7	647	52,486	476,923
Unknown	0.0	0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	0	2	4
Race												
White	1.1	90	12.8	42.9	42.7	5.3	5.4	2.4	1.3	701	46,632	405,827
African American	0.9	68	12.3	45.9	43.8	4.3	3.8	1.1	1.1	551	6,448	58,325
Other/unknown	0.6	49	7.4	48.3	43.4	3.4	3.2	1.1	0.6	655	64,092	577,621
Use of Nursing Facilities^f												
Entire year	8.4	781	5.8	8.0	8.0	2.7	26.7	26.7	28.0	13,366	75	673
Part year	8.9	684	6.6	6.4	7.3	8.3	17.4	33.0	27.5	10,335	109	1,104
None	0.8	65	10.0	46.1	43.2	4.2	4.1	1.6	0.9	649	116,988	1,039,996
Maintenance Assistance Status												
Cash	1.6	128	14.2	38.8	40.5	6.1	8.3	4.0	2.3	901	41,082	380,322
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.3	22	4.9	51.2	44.5	2.7	1.3	0.2	0.1	451	63,446	543,071
Other/unknown	0.7	66	7.3	43.5	45.0	5.3	4.5	1.2	0.5	905	12,644	118,380

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In ten states (DE, IA, IL, NC, NE, NY, TN, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In ten states (DE, IA, IL, NC, NE, NY, TN, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5
 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
All	0.8	\$66	\$79	0.3	\$47	\$153	0.1	\$5	\$91	0.5	\$14	\$30
Age												
5 and younger	0.3	23	85	0.1	18	227	0.0	1	46	0.2	4	24
6-14	0.3	27	90	0.1	22	152	0.0	1	67	0.1	4	28
15-20	0.5	55	102	0.2	44	206	0.0	3	78	0.3	8	28
21-44	1.5	114	74	0.5	77	153	0.1	9	115	0.9	28	29
45-64	4.5	329	73	1.7	214	127	0.3	30	103	2.5	84	33
65-74	3.7	223	61	1.4	151	108	0.2	18	76	2.0	53	26
75-84	3.7	189	52	1.4	126	89	0.2	17	67	2.0	46	23
85 and older	2.2	132	59	0.8	84	100	0.2	15	85	1.2	32	26
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility^d												
Aged	3.4	194	58	1.3	128	100	0.2	20	93	1.9	46	25
Disabled	4.6	401	88	1.9	294	156	0.3	28	99	2.4	78	33
Adults	1.0	63	63	0.3	37	145	0.1	7	120	0.7	19	28
Children	0.3	24	80	0.1	19	157	0.0	1	55	0.2	4	26
Unknown	1.9	203	104	0.7	143	198	0.1	24	191	1.1	35	32
Gender												
Female	1.0	69	71	0.3	46	135	0.1	6	97	0.6	17	29
Male	0.7	62	94	0.3	48	180	0.0	3	80	0.4	11	31
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	1.1	90	82	0.4	65	146	0.1	7	114	0.6	19	31
African American	0.9	68	73	0.4	51	134	0.0	4	95	0.5	13	26
Other/unknown	0.6	49	77	0.2	34	168	0.0	3	70	0.4	11	28
Use of Nursing Facilities^e												
Entire year	8.4	781	93	2.3	482	206	0.4	39	105	5.7	251	44
Part year	8.9	684	77	2.8	441	155	0.5	40	80	5.5	202	36
None	0.8	65	79	0.3	46	153	0.1	5	91	0.5	14	29
Maintenance Assistance Status												
Cash	1.6	128	79	0.6	89	149	0.1	10	100	0.9	29	31
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Poverty related	0.3	22	73	0.1	16	153	0.0	2	69	0.2	4	25
Other/unknown	0.7	66	97	0.3	53	177	0.0	3	75	0.3	10	30

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users ^e				
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.2	0.0	0.0	0.2	\$14	\$7	\$1	\$5	\$60	\$183	\$54	\$31	89,590	\$5,385,080	38,319	32.7	388,835
Biologicals	0.4	0.4	0.0	0.0	658	658	0	0	1467	1,467	0	0	2,079	3,049,675	501	0.4	4,635
Antineoplastic Agents	0.6	0.2	0.0	0.4	195	164	8	23	328	1,087	496	53	2,784	914,304	445	0.4	4,694
Endocrine/Metabolic Drugs	0.6	0.2	0.1	0.3	31	20	4	8	55	98	46	28	68,034	3,771,484	12,287	10.5	121,201
Cardiovascular Agents	1.5	0.4	0.1	0.9	60	32	10	18	41	74	83	20	103,437	4,290,451	6,764	5.8	71,020
Respiratory Agents	0.4	0.2	0.0	0.2	27	23	0	4	68	102	69	23	79,725	5,429,945	19,381	16.5	201,081
Gastrointestinal Agents	0.6	0.3	0.0	0.2	66	45	9	12	111	132	472	51	51,331	5,707,507	8,400	7.2	86,673
Genitourinary Agents	0.3	0.1	0.0	0.1	16	10	3	4	58	80	69	31	10,364	598,567	3,679	3.1	36,584
CNS Drugs	1.3	0.6	0.1	0.5	126	102	8	16	98	159	87	29	168,484	16,565,910	12,934	11.0	131,952
Stimulants/Anti-obesity/Anorexia	0.7	0.5	0.0	0.1	78	71	2	5	115	130	151	41	23,551	2,706,045	3,247	2.8	34,764
Miscellaneous Psychological/Neurological Agents	0.6	0.6	0.0	0.0	216	214	0	1	349	355	147	117	2,047	715,222	301	0.3	3,311
Analgesics and Anesthetics	0.5	0.1	0.0	0.4	27	11	3	13	56	214	298	31	109,421	6,174,830	22,826	19.5	224,646
Neuromuscular Agents	0.9	0.4	0.0	0.5	73	50	3	21	79	132	78	41	74,037	5,883,763	7,670	6.5	80,073
Nutritional Products	0.4	0.0	0.0	0.3	8	1	1	7	20	31	17	20	18,724	376,287	5,007	4.3	47,508
Hematological Agents	0.7	0.2	0.1	0.4	283	272	2	9	388	1,246	26	21	10,238	3,969,175	1,392	1.2	14,010
Topical Products	0.2	0.1	0.0	0.1	10	6	0	4	51	113	58	26	48,401	2,477,599	23,024	19.6	236,706
Miscellaneous Products	0.2	0.1	0.0	0.0	19	15	2	3	122	118	208	115	3,546	432,407	2,088	1.8	22,269
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	19	0	0	0	91	0	0	0	1,022	92,946	464	0.4	4,822
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	866,815	68,541,197	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2006.

Benef(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Top 10 Drug Groups	Users			Among Users				
	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month	
ANTIPSYCHOTICS	\$10,830,218	5,285	4.5	57,401	1.0	\$182	\$189	
ANTICONVULSANT	5,061,458	4,770	4.1	51,500	0.9	105	98	
ANTIDEPRESSANTS	4,242,651	10,527	9.0	109,053	0.7	56	39	
ANALGESICS - Narcotic	3,958,428	25,000	21.3	249,047	0.3	53	16	
ULCER DRUGS	3,919,724	7,240	6.2	75,274	0.5	100	52	
ANTIASTHMATIC	3,575,889	17,613	15.0	185,258	0.3	76	19	
PASSIVE IMMUNIZING AGENTS	3,043,021	424	0.4	3,806	0.5	1,524	800	
MISC. HEMATOLOGICAL	2,981,200	298	0.3	3,162	0.9	1,000	943	
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	2,706,045	3,723	3.2	40,256	0.6	115	67	
ANTIDIABETIC	1,712,293	3,012	2.6	31,707	0.8	64	54	
Total	42,030,927	77,892	n.a.	806,464	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2006. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement; n.a. = not applicable.

Nondual Medicaid Beneficiaries

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	All Top 10 Drug Groups				ANTIPSYCHOTICS				ANTICONVULSANT			
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	399,910	\$42,030,927	5,285	4.5	57,401	1.0	\$189	4,770	4.1	51,500	0.9	\$98
Female												
All Females	244,986	21,839,073	2,745	4.2	29,498	1.0	164	2,949	4.6	31,704	0.9	97
Female, Disabled												
All Ages	129,330	12,043,991	1,297	30.4	14,794	1.4	228	1,406	33.0	15,958	1.3	127
5 and younger	691	298,820	0	0.0	0	0.0	0	18	9.0	203	0.5	52
6-14	2,414	355,871	63	21.0	751	0.6	132	75	25.0	896	1.0	199
15-20	3,641	484,704	93	31.3	1,033	0.8	157	100	33.7	1,099	0.9	162
21-44	39,127	3,763,415	479	37.1	5,507	1.4	246	483	37.4	5,509	1.4	136
45-64	81,535	6,964,925	648	31.0	7,363	1.6	233	718	34.4	8,107	1.3	110
65-74	1,833	165,815	13	16.5	128	1.4	307	11	13.9	132	1.0	63
75-84	89	10,441	1	20.0	12	0.2	88	1	20.0	12	0.5	62
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	115,656	9,795,082	1,448	2.4	14,704	0.5	100	1,543	2.6	15,746	0.6	67
5 and younger	5,990	1,335,854	11	0.1	120	0.5	79	41	0.3	445	0.3	52
6-14	15,216	1,422,583	283	1.7	3,028	0.7	133	172	1.0	1,832	0.7	95
15-20	19,488	1,576,092	471	4.6	4,975	0.6	109	281	2.7	2,895	0.7	85
21-44	55,631	3,909,424	573	3.6	5,463	0.4	73	846	5.3	8,451	0.5	57
45-64	13,234	1,123,751	85	4.8	831	0.6	110	169	9.5	1,724	0.5	60
65-74	3,210	235,020	15	6.1	180	0.9	110	22	9.0	256	0.6	59
75-84	2,484	161,122	8	3.8	95	1.0	137	10	4.8	120	1.0	55
85 and older	403	31,236	2	3.5	12	1.0	117	2	3.5	23	1.0	47
Male												
All Males	154,924	20,191,854	2,540	4.8	27,903	1.1	214	1,821	3.5	19,796	1.0	101
Male, Disabled												
All Ages	81,391	11,397,254	1,335	31.4	14,855	1.4	276	1,035	24.3	11,597	1.2	119
5 and younger	1,293	371,870	11	3.9	113	1.1	156	39	13.8	452	0.7	82
6-14	7,034	1,329,963	195	32.3	2,229	0.9	193	149	24.7	1,722	1.0	117
15-20	6,549	2,560,904	153	31.6	1,776	1.2	249	125	25.8	1,435	1.1	146
21-44	26,227	3,088,221	593	50.9	6,512	1.5	303	340	29.2	3,758	1.3	118
45-64	39,288	3,981,564	373	22.3	4,105	1.5	296	378	22.6	4,183	1.2	114
65-74	987	62,385	10	22.7	120	1.2	143	4	9.1	47	2.3	58
75-84	13	2,347	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Medicaid Beneficiaries

TABLE ND.7A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTICONVULSANT				
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles												
All Ages	73,533	8,794,600	1,205	2.5	13,048	0.8	145	786	1.6	8,199	0.7	75
5 and younger	8,635	1,985,715	14	0.1	161	0.2	51	54	0.3	547	0.4	82
6-14	29,347	3,264,072	607	3.4	6,855	0.8	155	259	1.5	2,930	0.8	78
15-20	17,370	2,170,190	468	5.2	4,948	0.8	146	216	2.4	2,186	0.8	96
21-44	10,357	751,719	79	1.9	734	0.3	76	163	3.8	1,582	0.4	54
45-64	5,684	457,136	30	2.3	271	0.5	101	82	6.3	813	0.5	48
65-74	1,180	91,079	3	2.2	36	0.8	281	7	5.0	84	0.8	82
75-84	854	67,520	3	3.4	35	0.8	175	4	4.5	45	0.9	45
85 and older	106	7,169	1	3.7	8	0.9	57	1	3.7	12	0.2	8
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2006. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	ANTIDEPRESSANTS					ANALGESICS - Narcotic					ULCER DRUGS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	10,527	9.0	109,053	0.7	\$39	25,000	21.3	249,047	0.3	\$16	7,240	6.2	75,274	0.5	\$52
Female															
All Females	7,608	11.8	78,071	0.7	40	17,399	26.9	171,851	0.3	15	4,867	7.5	50,608	0.5	52
Female, Disabled															
All Ages	2,464	57.8	27,857	1.1	58	3,271	76.8	37,327	0.5	38	1,672	39.2	19,057	0.8	78
5 and younger	0	0.0	0	0.0	0	18	9.0	210	0.1	1	44	22.0	501	0.3	24
6-14	31	10.3	368	0.6	19	40	13.3	464	0.1	1	29	9.7	348	0.3	48
15-20	98	33.0	1,075	0.7	39	80	26.9	920	0.2	3	43	14.5	492	0.5	70
21-44	810	62.7	9,242	1.1	57	1,106	85.6	12,664	0.4	34	400	31.0	4,589	0.8	70
45-64	1,497	71.7	16,879	1.2	60	1,985	95.1	22,614	0.5	44	1,115	53.4	12,665	0.9	83
65-74	27	34.2	281	1.0	56	39	49.4	419	0.5	13	38	48.1	426	1.0	123
75-84	1	20.0	12	0.8	70	3	60.0	36	0.2	5	3	60.0	36	0.5	62
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	5,144	8.5	50,214	0.4	30	14,128	23.4	134,524	0.3	9	3,195	5.3	31,551	0.3	36
5 and younger	6	0.0	68	0.5	48	396	2.6	4,173	0.1	1	237	1.6	2,242	0.2	18
6-14	365	2.2	3,915	0.5	23	1,081	6.4	11,570	0.1	2	253	1.5	2,746	0.2	21
15-20	987	9.5	9,896	0.5	26	2,624	25.4	25,332	0.2	3	499	4.8	5,121	0.3	24
21-44	3,130	19.7	29,827	0.4	30	8,758	55.1	80,449	0.3	11	1,639	10.3	15,492	0.3	36
45-64	578	32.5	5,629	0.5	40	1,075	60.5	10,781	0.4	21	404	22.7	4,095	0.4	55
65-74	51	20.8	593	0.6	38	102	41.6	1,176	0.3	10	98	40.0	1,105	0.8	74
75-84	20	9.5	226	1.2	47	79	37.6	903	0.2	8	54	25.7	641	0.9	85
85 and older	7	12.3	60	1.0	45	13	22.8	140	0.2	4	11	19.3	109	1.0	105
Male															
All Males	2,919	5.6	30,982	0.7	36	7,601	14.5	77,196	0.3	17	2,373	4.5	24,666	0.5	52
Male, Disabled															
All Ages	1,306	30.7	14,496	1.0	47	1,892	44.5	21,000	0.5	43	964	22.7	10,695	0.8	77
5 and younger	1	0.4	12	1.0	46	31	11.0	339	0.2	2	46	16.3	504	0.3	26
6-14	101	16.7	1,108	0.8	28	59	9.8	685	0.1	3	45	7.5	538	0.6	59
15-20	111	22.9	1,311	0.8	40	109	22.5	1,220	0.1	2	42	8.7	497	0.6	76
21-44	401	34.4	4,424	1.2	51	479	41.1	5,324	0.4	22	232	19.9	2,602	0.9	72
45-64	681	40.7	7,524	1.0	48	1,194	71.4	13,199	0.6	58	583	34.9	6,382	0.9	85
65-74	11	25.0	117	1.1	39	20	45.5	233	0.2	19	16	36.4	172	1.6	104
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Medicaid Beneficiaries

TABLE ND.7B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	ANTIDEPRESSANTS					ANALGESICS - Narcotic					ULCER DRUGS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
Male, Other Eligibles															
All Ages	1,613	3.3	16,486	0.5	28	5,709	11.8	56,196	0.2	7	1,409	2.9	13,971	0.3	33
5 and younger	13	0.1	155	0.3	8	597	3.8	6,251	0.1	1	347	2.2	3,306	0.2	17
6-14	432	2.4	4,797	0.6	25	1,133	6.4	12,278	0.1	2	237	1.3	2,564	0.2	28
15-20	584	6.5	5,967	0.6	30	1,607	17.9	15,700	0.1	3	216	2.4	2,240	0.3	25
21-44	386	9.0	3,585	0.3	26	1,803	42.2	16,397	0.3	15	350	8.2	3,200	0.3	40
45-64	176	13.5	1,750	0.5	33	504	38.8	4,865	0.4	20	202	15.6	2,029	0.4	55
65-74	12	8.6	125	0.2	15	36	25.9	399	0.2	11	34	24.5	365	0.5	52
75-84	7	7.9	76	0.5	33	25	28.1	268	0.2	4	21	23.6	245	0.9	77
85 and older	3	11.1	31	0.4	22	4	14.8	38	0.2	3	2	7.4	22	0.7	48
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2006. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	ANTIASTHMATIC					PASSIVE IMMUNIZING AGENTS					MISC. HEMATOLOGICAL				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	17,613	15.0	185,258	0.3	\$19	424	0.4	3,806	0.5	\$800	298	0.3	3,162	0.9	\$943
Female															
All Females	9,794	15.1	102,598	0.3	20	194	0.3	1,724	0.5	738	156	0.2	1,703	1.1	90
Female, Disabled															
All Ages	1,998	46.9	22,740	0.4	36	35	0.8	360	0.5	674	108	2.5	1,205	1.3	98
5 and younger	76	38.0	877	0.2	16	35	17.5	360	0.5	674	0	0.0	0	0.0	0
6-14	79	26.3	937	0.3	16	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	64	21.5	697	0.3	46	0	0.0	0	0.0	0	0	0.0	0	0.0	0
21-44	506	39.2	5,700	0.3	28	0	0.0	0	0.0	0	15	1.2	173	1.4	79
45-64	1,218	58.4	13,908	0.5	41	0	0.0	0	0.0	0	86	4.1	957	1.2	101
65-74	55	69.6	621	0.5	42	0	0.0	0	0.0	0	7	8.9	75	1.5	100
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	7,796	12.9	79,858	0.2	16	159	0.3	1,364	0.5	755	48	0.1	498	0.9	70
5 and younger	2,076	13.8	21,630	0.2	10	147	1.0	1,267	0.5	812	0	0.0	0	0.0	0
6-14	1,929	11.4	20,791	0.2	16	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	1,201	11.6	12,165	0.2	15	1	0.0	12	0.1	9	0	0.0	0	0.0	0
21-44	2,066	13.0	19,895	0.2	17	11	0.1	85	0.1	16	17	0.1	168	0.3	41
45-64	399	22.4	3,938	0.4	31	0	0.0	0	0.0	0	11	0.6	109	0.4	59
65-74	66	26.9	778	0.4	41	0	0.0	0	0.0	0	8	3.3	96	1.5	103
75-84	51	24.3	589	0.4	52	0	0.0	0	0.0	0	10	4.8	104	1.5	95
85 and older	8	14.0	72	0.4	41	0	0.0	0	0.0	0	2	3.5	21	0.9	84
Male															
All Males	7,819	14.9	82,660	0.2	18	230	0.4	2,082	0.5	850	142	0.3	1,459	0.7	1,939
Male, Disabled															
All Ages	1,023	24.1	11,514	0.4	36	38	0.9	386	0.5	679	90	2.1	977	0.8	2,213
5 and younger	99	35.1	1,142	0.3	29	38	13.5	386	0.5	679	0	0.0	0	0.0	0
6-14	132	21.9	1,536	0.3	26	0	0.0	0	0.0	0	2	0.3	24	0.8	17,695
15-20	86	17.8	996	0.3	42	0	0.0	0	0.0	0	3	0.6	29	0.9	57,466
21-44	174	14.9	1,910	0.3	27	0	0.0	0	0.0	0	6	0.5	66	0.4	50
45-64	510	30.5	5,719	0.4	42	0	0.0	0	0.0	0	78	4.7	846	0.8	78
65-74	21	47.7	199	0.4	39	0	0.0	0	0.0	0	1	2.3	12	0.8	103
75-84	1	100.0	12	1.1	196	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Medicaid Beneficiaries

TABLE ND.7C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
 BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	ANTIASTHMATIC						PASSIVE IMMUNIZING AGENTS					MISC. HEMATOLOGICAL				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean		Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean		Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean		
				Rx per Benefit Month	Mean Rx \$ per Benefit Month				Rx per Benefit Month	Mean Rx \$ per Benefit Month				Rx per Benefit Month	Mean Rx \$ per Benefit Month	
Male, Other Eligibles																
All Ages	6,796	14.1	71,146	0.2	15	192	0.4	1,696	0.6	889	52	0.1	482	0.6	1,383	
5 and younger	2,910	18.5	30,121	0.2	11	192	1.2	1,696	0.6	889	2	0.0	24	0.5	287	
6-14	2,538	14.3	27,319	0.2	16	0	0.0	0	0.0	0	3	0.0	24	0.3	8,221	
15-20	766	8.5	7,793	0.3	21	0	0.0	0	0.0	0	4	0.0	43	0.3	10,217	
21-44	330	7.7	3,178	0.3	20	0	0.0	0	0.0	0	14	0.3	106	0.5	59	
45-64	164	12.6	1,740	0.3	29	0	0.0	0	0.0	0	18	1.4	170	0.6	60	
65-74	50	36.0	551	0.5	50	0	0.0	0	0.0	0	3	2.2	27	2.0	108	
75-84	33	37.1	393	0.5	60	0	0.0	0	0.0	0	6	6.7	68	0.7	49	
85 and older	5	18.5	51	0.6	78	0	0.0	0	0.0	0	2	7.4	20	0.5	22	
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0	

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2006. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	STIMULANTS/ANTI-OBESITY/ANOREXIANTS					ANTIDIABETIC						
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Beneficiaries	Number of Benefit Months
All	3,723	3.2	40,256	0.6	\$67	3,012	2.6	31,707	0.8	\$54	117,172	1,041,773
Female												
All Females	1,195	1.8	12,792	0.5	72	2,013	3.1	21,264	0.8	53	64,684	564,846
Female, Disabled												
All Ages	199	4.7	2,294	0.6	98	1,029	24.2	11,625	1.0	62	4,260	45,720
5 and younger	2	1.0	22	0.3	813	1	0.5	12	1.4	120	200	1,983
6-14	45	15.0	535	0.6	61	8	2.7	92	0.9	75	300	3,382
15-20	26	8.8	291	0.9	102	10	3.4	118	0.5	27	297	3,121
21-44	60	4.6	679	0.7	99	209	16.2	2,344	1.0	59	1,292	14,196
45-64	66	3.2	767	0.5	100	776	37.2	8,796	1.1	63	2,087	22,139
65-74	0	0.0	0	0.0	0	21	26.6	215	1.0	51	79	839
75-84	0	0.0	0	0.0	0	4	80.0	48	1.0	112	5	60
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Female, Other Eligibles												
All Ages	996	1.6	10,498	0.5	66	984	1.6	9,639	0.6	41	60,424	519,126
5 and younger	20	0.1	218	0.5	50	8	0.1	87	1.1	78	15,030	131,221
6-14	506	3.0	5,473	0.6	58	47	0.3	487	0.7	56	16,869	163,003
15-20	228	2.2	2,437	0.5	55	75	0.7	694	0.6	39	10,341	88,709
21-44	204	1.3	2,007	0.5	94	494	3.1	4,603	0.5	36	15,894	115,437
45-64	38	2.1	363	0.6	126	189	10.6	1,870	0.6	47	1,778	15,498
65-74	0	0.0	0	0.0	0	91	37.1	1,005	0.8	41	245	2,559
75-84	0	0.0	0	0.0	0	68	32.4	749	1.0	39	210	2,235
85 and older	0	0.0	0	0.0	0	12	21.1	144	0.9	65	57	464
Male												
All Males	2,528	4.8	27,464	0.6	65	999	1.9	10,443	0.8	57	52,486	476,923
Male, Disabled												
All Ages	369	8.7	4,254	0.7	78	577	13.6	6,401	0.9	56	4,252	44,146
5 and younger	14	5.0	155	0.3	48	3	1.1	30	0.4	30	282	2,687
6-14	210	34.8	2,433	0.6	68	5	0.8	60	0.7	32	603	6,709
15-20	92	19.0	1,082	0.8	89	12	2.5	144	0.9	78	484	5,194
21-44	33	2.8	364	0.6	87	85	7.3	925	1.2	56	1,166	12,025
45-64	19	1.1	208	0.7	136	459	27.5	5,087	0.8	56	1,672	17,068
65-74	1	2.3	12	0.3	49	13	29.5	155	1.3	39	44	451
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Nondual Medicaid Beneficiaries

TABLE ND.7D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	STIMULANTS/ANTI-OBESITY/ANOREXIANTS						ANTIDIABETIC					
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean		Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean		Number of Beneficiaries	Number of Benefit Months
				Rx per Month	Mean Rx \$ per Benefit				Rx per Month	Mean Rx \$ per Benefit		
Male, Other Eligibles												
All Ages	2,159	4.5	23,210	0.6	63	422	0.9	4,042	0.7	58	48,234	432,777
5 and younger	57	0.4	631	0.4	34	8	0.1	68	0.6	66	15,708	137,322
6-14	1,589	9.0	17,202	0.6	63	58	0.3	624	0.7	86	17,743	171,430
15-20	469	5.2	4,965	0.6	65	47	0.5	462	0.7	85	8,960	78,634
21-44	41	1.0	383	0.5	88	122	2.9	1,104	0.5	45	4,269	31,646
45-64	3	0.2	29	0.2	72	135	10.4	1,218	0.7	49	1,299	11,147
65-74	0	0.0	0	0.0	0	33	23.7	340	1.3	55	139	1,399
75-84	0	0.0	0	0.0	0	16	18.0	192	1.2	52	89	970
85 and older	0	0.0	0	0.0	0	3	11.1	34	0.7	11	27	229
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	4

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2006. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

TABLE ND.8
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BENEFICIARY CHARACTERISTIC^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	\$781	8.4	75	673
Age				
0-64	908	9.5	60	528
65-74	179	2.9	6	57
75-84	541	6.0	5	51
85 and older	226	4.9	4	37
Unknown	0	0.0	0	0
Gender				
Female	706	8.6	40	398
Male	889	8.3	35	275
Unknown	0	0.0	0	0
Race				
White	923	10.8	35	278
African American	530	6.2	6	63
Other/unknown	710	6.9	34	332
Basis of Eligibility^c				
Aged	327	4.6	13	136
Disabled	898	9.4	61	536
Adults	0	0.0	1	1
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2006 Medicaid enrollment. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Benef(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

TABLE ND.9
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,
 BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d, e}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users				
	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.2	0.0	0.3	\$78	\$62	\$1	\$14	\$162	\$323	\$92	\$52	204	\$33,067	41	54.7	425
Biologicals	0.0	0.0	0.0	0.0	0	0	0	0	0	0	0	0	0	0	0	0.0	0
Antineoplastic Agents	0.2	0.0	0.0	0.2	29	0	0	29	139	0	0	139	5	693	2	2.7	24
Endocrine/Metabolic Drugs	1.5	0.8	0.1	0.6	94	73	8	13	62	94	65	20	442	27,303	31	41.3	291
Cardiovascular Agents	2.6	0.5	0.2	1.9	94	35	16	43	36	72	78	22	833	29,889	34	45.3	319
Respiratory Agents	0.7	0.5	0.0	0.2	63	57	0	6	85	109	91	26	167	14,208	23	30.7	225
Gastrointestinal Agents	1.6	0.6	0.0	1.0	116	83	0	32	70	143	21	30	804	56,375	51	68.0	488
Genitourinary Agents	0.5	0.2	0.0	0.2	31	24	1	6	65	98	47	29	58	3,783	13	17.3	123
CNS Drugs	2.1	0.8	0.1	1.2	205	148	15	42	97	185	114	36	1,123	109,096	55	73.3	533
Stimulants/Anti-obesity/Anorexia	0.8	0.2	0.0	0.6	58	41	0	17	74	247	0	28	38	2,807	4	5.3	48
Miscellaneous Psychological/Neurological Agents	0.8	0.8	0.0	0.0	737	737	0	0	884	884	0	0	50	44,220	5	6.7	60
Analgesics and Anesthetics	1.4	0.1	0.0	1.3	177	76	6	95	130	1,217	154	76	520	67,823	43	57.3	384
Neuromuscular Agents	1.9	0.2	0.0	1.7	159	33	1	125	83	170	60	73	909	75,229	48	64.0	472
Nutritional Products	0.9	0.0	0.0	0.9	17	0	0	17	18	0	0	18	162	2,932	17	22.7	172
Hematological Agents	1.0	0.5	0.0	0.5	386	379	0	7	382	782	0	13	96	36,633	15	20.0	95
Topical Products	0.5	0.1	0.1	0.3	36	7	17	12	70	87	201	35	213	14,931	40	53.3	416
Miscellaneous Products	0.2	0.1	0.0	0.1	4	1	0	3	21	22	0	20	3	62	3	4.0	16
Unknown Therapeutic Category	0.5	0.0	0.0	0.0	58	0	0	0	126	0	0	0	53	6,663	12	16.0	114
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	5,680	525,714	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.
 a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.
 b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2006. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.
 e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.
 In Alaska, 0.5 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.
 Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,
 BY TOP-10 DRUG GROUP^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Top 10 Drug Groups in Nursing Facilities	Users				Among Users			
	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month	
ANTIPSYCHOTICS	\$60,127	21	28.0	228	1.1	\$241	\$264	
ANTICONVULSANT	53,803	47	62.7	484	1.1	97	111	
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	44,220	6	8.0	72	0.7	884	614	
ULCER DRUGS	43,401	41	54.7	402	1.1	100	108	
ANTIDEPRESSANTS	39,017	55	73.3	559	1.1	62	70	
ANALGESICS - Narcotic	37,328	51	68.0	476	0.9	87	78	
HEMATOPOIETIC AGENTS	28,810	11	14.7	90	0.8	424	320	
ANALGESICS - ANTI-INFLAMMATORY	29,883	7	9.3	82	0.7	524	364	
MUSCULOSKELETAL THERAPY AGENTS	20,911	24	32.0	247	1.4	61	85	
ANTIDIABETIC	18,758	20	26.7	215	1.0	90	87	
Total	376,258	283	n.a.	2,855	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2006 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement; n.a. = not applicable.

Nondual Medicaid Beneficiaries

TABLE ND.10A
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST
 AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTICONVULSANT				
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	3,018	\$376,258	21	28.0	228	1.1	\$264	47	62.7	484	1.1	\$111
Female												
All Females	1,830	213,474	11	27.5	123	0.7	186	28	70.0	313	1.2	101
Female, Disabled												
All Ages	1,654	193,213	6	19.4	63	0.7	189	26	83.9	289	1.2	107
64 or younger	1,654	193,213	6	20.0	63	0.7	189	26	86.7	289	1.2	107
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	176	20,261	5	55.6	60	0.7	181	2	22.2	24	1.1	31
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	78	5,792	1	25.0	12	1.0	242	2	50.0	24	1.1	31
75-84	65	12,231	4	133.3	48	0.6	166	0	0.0	0	0.0	0
85 and older	33	2,238	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male												
All Males	1,188	162,784	10	28.6	105	1.6	355	19	54.3	171	1.1	129
Male, Disabled												
All Ages	1,076	154,698	9	30.0	93	1.5	338	18	60.0	159	1.1	134
64 or younger	1,062	153,838	9	31.0	93	1.5	338	18	62.1	159	1.1	134
65-74	14	860	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	112	8,086	1	20.0	12	2.2	492	1	20.0	12	1.0	66
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	84	7,607	1	50.0	12	2.2	492	1	50.0	12	1.0	66
85 and older	28	479	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2006 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					ULCER DRUGS					ANTIDEPRESSANTS				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	6	8.0	72	0.7	\$614	41	54.7	402	1.1	\$108	55	73.3	559	1.1	\$70
Female															
All Females	3	7.5	36	0.9	664	22	55.0	236	1.1	111	28	70.0	301	1.4	85
Female, Disabled															
All Ages	3	9.7	36	0.9	664	17	54.8	176	1.0	111	27	87.1	298	1.4	85
64 or younger	3	10.0	36	0.9	664	17	56.7	176	1.0	111	27	90.0	298	1.4	85
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	0	0.0	0	0.0	0	5	55.6	60	1.2	113	1	11.1	3	3.0	81
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	2	50.0	24	1.6	89	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	2	66.7	24	1.0	142	1	33.3	3	3.0	81
85 and older	0	0.0	0	0.0	0	1	100.0	12	0.9	104	0	0.0	0	0.0	0
Male															
All Males	3	8.6	36	0.5	565	19	54.3	166	1.1	103	27	77.1	258	0.8	53
Male, Disabled															
All Ages	3	10.0	36	0.5	565	18	60.0	156	1.1	109	25	83.3	236	0.8	54
64 or younger	3	10.3	36	0.5	565	18	62.1	156	1.1	109	24	82.8	228	0.8	53
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	100.0	8	0.9	68
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles															
All Ages	0	0.0	0	0.0	0	1	20.0	10	0.9	14	2	40.0	22	0.9	40
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	50.0	12	1.1	61
85 and older	0	0.0	0	0.0	0	1	33.3	10	0.9	14	1	33.3	10	0.6	15
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2006 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	ANALGESICS - Narcotic					HEMATOPOIETIC AGENTS					ANALGESICS - ANTI-INFLAMMATORY				
	Number of Users	Users as %	Number of	Mean	Mean	Number of Users	Users as %	Number of	Mean	Mean	Number of Users	Users as %	Number of	Mean	Mean
		of All-Year					Benefit Months					Rx			
	Residents	Among Users	Number			Residents	Among Users	Number			Residents	Among Users	Number		
All	51	68.0	476	0.9	\$78	11	14.7	90	0.8	\$320	7	9.3	82	0.7	\$364
Female															
All Females	24	60.0	244	1.0	109	4	10.0	28	1.2	122	6	15.0	72	0.8	415
Female, Disabled															
All Ages	21	67.7	217	1.2	122	3	9.7	25	1.3	114	6	19.4	72	0.8	415
64 or younger	21	70.0	217	1.2	122	3	10.0	25	1.3	114	6	20.0	72	0.8	415
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles															
All Ages	3	33.3	27	0.1	1	1	11.1	3	0.3	193	0	0.0	0	0.0	0
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	1	25.0	12	0.1	1	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	2	66.7	15	0.1	1	1	33.3	3	0.3	193	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male															
All Males	27	77.1	232	0.8	47	7	20.0	62	0.6	410	1	2.9	10	0.1	3
Male, Disabled															
All Ages	21	70.0	166	1.0	64	5	16.7	38	0.4	667	0	0.0	0	0.0	0
64 or younger	21	72.4	166	1.0	64	5	17.2	38	0.4	667	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles															
All Ages	6	120.0	66	0.2	3	2	40.0	24	0.9	2	1	20.0	10	0.1	3
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	3	150.0	36	0.3	4	2	100.0	24	0.9	2	0	0.0	0	0.0	0
85 and older	3	100.0	30	0.1	3	0	0.0	0	0.0	0	1	33.3	10	0.1	3
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.
 a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.
 b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 d. The top 10 drug groups were determined based on total 2006 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.
 Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	MUSCULOSKELETAL THERAPY AGENTS						ANTIDIABETIC						
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$		Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
All	24	32.0	247	1.4	\$85		20	26.7	215	1.0	\$87	75	673
Female													
All Females	14	35.0	157	1.5	96		11	27.5	117	0.9	72	40	398
Female, Disabled													
All Ages	14	45.2	157	1.5	96		10	32.3	105	0.8	71	31	310
64 or younger	14	46.7	157	1.5	96		10	33.3	105	0.8	71	30	309
65-74	0	0.0	0	0.0	0		0	0.0	0	0.0	0	1	1
75-84	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
Female, Other Eligibles													
All Ages	0	0.0	0	0.0	0		1	11.1	12	1.8	82	9	88
64 or younger	0	0.0	0	0.0	0		0	0.0	0	0.0	0	1	1
65-74	0	0.0	0	0.0	0		0	0.0	0	0.0	0	4	48
75-84	0	0.0	0	0.0	0		0	0.0	0	0.0	0	3	27
85 and older	0	0.0	0	0.0	0		1	100.0	12	1.8	82	1	12
Male													
All Males	10	28.6	90	1.2	65		9	25.7	98	1.1	106	35	275
Male, Disabled													
All Ages	10	33.3	90	1.2	65		8	26.7	88	1.1	117	30	226
64 or younger	9	31.0	82	1.2	67		8	27.6	88	1.1	117	29	218
65-74	1	100.0	8	0.9	40		0	0.0	0	0.0	0	1	8
75-84	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
Male, Other Eligibles													
All Ages	0	0.0	0	0.0	0		1	20.0	10	0.8	8	5	49
64 or younger	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0		0	0.0	0	0.0	0	2	24
85 and older	0	0.0	0	0.0	0		1	33.3	10	0.8	8	3	25
Unknown	0	0.0	0	0.0	0		0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.
 a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2006. A total of 109 beneficiaries who were in nursing facilities for part of their enrollment and their 1,104 benefit months were excluded from the analysis.
 b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2006. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
 c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
 d. The top 10 drug groups were determined based on total 2006 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medi-span.com/master-drug-database.aspx>.
 Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.11
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2006

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	Part D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx \$ as a Percentage of All Nondual Rx \$	Total Number of Beneficiaries	
All	9,267	7.9	0.4	42,232	\$7	\$786,166	\$19	1.1	117,172	
Age										
5 and younger	1,519	4.9	0.1	2,903	2	61,187	21	1.0	31,222	
6-14	653	1.8	0.0	1,698	1	36,806	22	0.4	35,515	
15-20	1,234	6.1	0.2	3,239	3	56,218	17	0.6	20,082	
21-44	3,732	16.5	0.7	16,551	13	295,440	18	1.5	22,621	
45-64	1,963	28.7	2.4	16,267	46	313,443	19	1.4	6,836	
65-74	92	18.1	1.8	933	29	14,536	16	1.2	507	
75-84	59	19.3	1.9	571	25	7,528	13	1.2	305	
85 and older	15	17.9	0.8	70	12	1,008	14	1.1	84	
Unknown	0	0.0	0.0	0	0	0	0	0.0	0	
Basis of Eligibility^c										
Aged	144	18.6	1.7	1,314	25	19,465	15	1.3	776	
Disabled	2,519	29.6	2.6	22,439	57	482,266	21	1.3	8,512	
Adults	3,905	13.9	0.5	13,195	7	201,939	15	1.5	28,122	
Children	2,672	3.4	0.1	5,198	1	81,060	16	0.5	79,598	
Unknown	27	16.5	0.5	86	9	1,436	17	0.6	164	
Gender										
Female	6,524	10.1	0.5	29,628	8	524,525	18	1.3	64,684	
Male	2,743	5.2	0.2	12,604	5	261,641	21	0.9	52,486	
Unknown	0	0.0	0.0	0	0	0	0	0.0	2	
Race										
White	4,242	9.1	0.5	23,871	10	488,550	20	1.3	46,632	
African American	357	5.5	0.3	1,703	4	26,212	15	0.7	6,448	
Other/unknown	4,668	7.3	0.3	16,658	4	271,404	16	1.0	64,092	
Use of Nursing Facilities^d										
Entire year	39	52.0	6.1	456	110	8,231	18	1.6	75	
Part year	79	72.5	8.2	892	190	20,705	23	2.7	109	
None	9,149	7.8	0.3	40,884	6	757,230	19	1.1	116,988	
Maintenance Assistance Status										
Cash	5,497	13.4	0.8	33,360	15	624,951	19	1.3	41,082	
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0	
Poverty related	2,979	4.7	0.1	5,888	1	79,204	13	0.7	63,446	
Other/unknown	791	6.3	0.2	2,984	6	82,011	27	1.0	12,644	

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2006.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D
 AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}
 ALASKA, 2006

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
All	0.0	\$1	\$19	\$0	\$0	1,041,773
Age						
5 and younger	0.0	0	21	0	0	273,217
6-14	0.0	0	22	0	0	344,524
15-20	0.0	0	17	0	0	175,658
21-44	0.1	2	18	0	1	173,304
45-64	0.2	5	19	0	3	65,852
65-74	0.2	3	16	0	1	5,248
75-84	0.2	2	13	0	0	3,277
85 and older	0.1	1	14	0	0	693
Unknown	0.0	0	0	0	0	0
Basis of Eligibility^c						
Aged	0.2	2	15	0	1	7,973
Disabled	0.2	5	21	0	3	89,866
Adults	0.1	1	15	0	1	210,169
Children	0.0	0	16	0	0	732,662
Unknown	0.1	1	17	0	1	1,103
Gender						
Female	0.1	1	18	0	1	564,846
Male	0.0	1	21	0	0	476,923
Unknown	0.0	0	0	0	0	4
Race						
White	0.1	1	20	0	1	405,827
African American	0.0	0	15	0	0	58,325
Other/unknown	0.0	0	16	0	0	577,621
Use of Nursing Facilities^d						
Entire year	0.7	12	18	0	7	673
Part year	0.8	19	23	0	9	1,104
None	0.0	1	19	0	0	1,039,996
Maintenance Assistance Status						
Cash	0.1	2	19	0	1	380,322
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	13	0	0	543,071
Other/unknown	0.0	1	27	0	0	118,380

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2006.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13
 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c}
 ALASKA, 2006

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	10,485	\$75	\$786,166	100.0	42,232	\$19	100.0
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	0	0	0	0.0	0	0	0.0
Drugs for cosmetic purposes	38	19	719	0.1	55	13	0.1
Cough and cold medications	514	103	52,933	6.7	957	55	2.3
Vitamins and minerals	1,786	87	156,132	19.9	8,471	18	20.1
Non-prescription drugs	3,243	28	89,242	11.4	8,617	10	20.4
Barbiturates	155	78	12,066	1.5	956	13	2.3
Benzodiazepines	4,127	104	428,037	54.4	21,438	20	50.8
Other Part D Excl Rx Drugs	622	76	47,037	6.0	1,738	27	4.1

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all non-dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2006. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2006. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Medicaid Beneficiaries

APPENDIX TABLE A.1
 CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
 NONDUAL BENEFICIARIES, ALASKA, 2006

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	117,172	776	8,512	28,122	79,598	164	1,041,773	7,973	89,866	210,169	732,662	1,103
Age												
5 and younger	31,222	0	482	0	30,740	0	273,217	0	4,670	0	268,547	0
6-14	35,515	0	903	2	34,610	0	344,524	0	10,091	7	334,426	0
15-20	20,082	0	781	5,322	13,974	5	175,658	0	8,315	38,879	128,447	17
21-44	22,621	1	2,458	19,799	274	89	173,304	3	26,221	145,323	1,242	515
45-64	6,836	16	3,759	2,992	0	69	65,852	148	39,207	25,934	0	563
65-74	507	376	123	7	0	1	5,248	3,924	1,290	26	0	8
75-84	305	299	6	0	0	0	3,277	3,205	72	0	0	0
85 and older	84	84	0	0	0	0	693	693	0	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	64,684	517	4,260	20,944	38,799	164	564,846	5,331	45,720	154,781	357,911	1,103
Male	52,486	259	4,252	7,178	40,797	0	476,923	2,642	44,146	55,388	374,747	0
Unknown	2	0	0	0	2	0	4	0	0	0	4	0
Race												
White	46,632	152	4,481	11,948	29,925	126	405,827	1,383	46,628	85,976	270,979	861
African American	6,448	16	518	1,379	4,531	4	58,325	120	5,464	10,489	42,223	29
Other/unknown	64,092	608	3,513	14,795	45,142	34	577,621	6,470	37,774	113,704	419,460	213
Use of Nursing Facilities^c												
Entire year	75	13	61	1	0	0	673	136	536	1	0	0
Part year	109	16	89	4	0	0	1,104	158	901	45	0	0
None	116,988	747	8,362	28,117	79,598	164	1,039,996	7,679	88,429	210,123	732,662	1,103
Maintenance Assistance Status												
Cash	41,082	736	7,645	15,816	16,885	0	380,322	7,739	80,876	130,875	160,832	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty related	63,446	0	0	10,217	53,065	164	543,071	0	0	62,200	479,768	1,103
Other/unknown	12,644	40	867	2,089	9,648	0	118,380	234	8,990	17,094	92,062	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	117,172	776	8,512	28,122	79,598	164	1,041,773	7,973	89,866	210,169	732,662	1,103
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
 b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
 c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
 Benef(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a
 NONDUAL BENEFICIARIES, ALASKA, 2006

	Beneficiaries and Benefit Months in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	117,172	1,041,773	117,172	1,041,773	0	0
Fee-for-service (FFS) all year	117,172	1,041,773	117,172	1,041,773	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2006 file for Alaska, released by CMS in 5/2009. This table was produced on 02/11/2010.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract;

MC = managed care; Rx = pharmacy benefit.

Nondual Medicaid Beneficiaries